ADDRESSING BOTH PATHWAYS

You can be a part of sparking a change in the approach to MS

Directly addressing smoldering neuroinflammation by crossing the blood-brain barrier at pharmacologically relevant levels may slow disease progression and subsequent disability accumulation.1

Occurring exclusively in the CNS, smoldering neuroinflammation has been largely inaccessible.2

Close-up of smoldering match brain

Emerging science reveals that smoldering neuroinflammation is a primary driver of disease progression that results in disability accumulation, and directly addressing this pathway remains an unmet need1,2

Direct targeting of both acute neuroinflammatory pathways in the periphery and smoldering neuroinflammation by penetrating into the CNS at pharmacologically relevant levels may help address relapses, MRI activity, and disease progression that ultimately results in disability accumulation.2

Both pathways play an important role1,2

Smoldering and acute neuroinflammation concurrently drive consequences in RMS

Addressing microglia in the CNS as well as B cells and T cells in the periphery may improve long-term outcomes2

Targeting both acute and smoldering neuroinflammation is important in addressing relapses and acute lesion activity and directly impacting the mechanisms that drive disease progression and resulting disability accumulation.2

Both acute and smoldering neuroinflammation may occur from the onset. When you address both pathways early, you could help prevent disease progression and impact long-term disability outcomes in patients with MS2,4,5

Keep exploring the future of MS management for your patients

Stay Connected

Receive updates on the evolving conversations around MS

Register Now

   References:

  1. Häusser-Kinzel S, Weber MS. The role of B cells and antibodies in multiple sclerosis, neuromyelitis optica, and related disorders. Front Immunol. 2019;10:201.
  2. Giovannoni G, Popescu V, Wuerfel J, et al. Smouldering multiple sclerosis: the ‘real MS’. Ther Adv Neurol Disord. 2022;15:17562864211066751. doi:10.1177/17562864211066751
  3. Kuhlmann T, Moccia M, Coetzee T, et al. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2023;22(1):78-88.
  4. Simpson A, Mowry EM, Newsome SD. Early aggressive treatment approaches for multiple sclerosis. Curr Treat Options Neurol. 2021;23(7):19.
  5. Scalfari A. MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - Yes. Mult Scler. 2021;27(7):1002-1004.